Enablers and barriers to rotavirus vaccine coverage in Assam, India- A qualitative study.

Background: Estimates suggest that 78,000 children died due to rotavirus gastroenteritis annually between 2011 and 2013 in India. The north eastern state of Assam reported 38.4% pediatric diarrheal admissions testing positive for rotavirus. Rotavirus vaccine (RVV) was introduced in Assam in 2017 following which the National Family Health Survey-5 (NFHS-5) (2019) revealed low RVV coverage in Assam with wide variation between the districts. the current study was conceptualized and undertaken to capture the enablers and barriers to RVV coverage in Assam. Methods: Qualitative study conducted in 5 randomly selected districts in Assam. Participants (key informants) were recruited by purposive sampling at each level of the health system including healthcare officials, service providers and caregivers based on availability. Thirty-five in-depth interviews (IDIs) and five focus group discussions (FGDs) were conducted. Interviews were tape recorded and transcribed. Data was coded and analyzed using the thematic framework approach. Results: Findings from the qualitative data collection were collated and analyzed under 7 identified themes. Difficult terrain, limited service provider availability and no catch-up training for new recruits were some of the barriers to RVV coverage. In contrast, Information, Education & Communication (IEC) in vernacular language, RVV safety profile, development partner support and adequate RVV supply were identified as some of the enablers of RVV coverage. Conclusion: Few broad recommendations to overcome identified barriers include comprehensive inter-sectoral coordination, regular monitoring and frequent refresher training sessions. There is a need for a future study utilizing existing coverage data and larger sample size to triangulate the findings of this study.

Prevalence and incidence of oral cancer and pre-cancerous lesions in indigenous populations: a systematic review protocol.

OBJECTIVE: This review will determine the prevalence and incidence of oral cancer and pre-cancerous lesions in indigenous populations. INTRODUCTION: There are approximately 476 million indigenous individuals worldwide. Oral cancer affected over 350,000 people globally in 2018, with approximately 80% of cases occurring in the indigenous population. Moreover, the incidence of pre-cancerous lesions is high in this population, accounting for 48.3%. Limited evidence exists regarding the burden of oral cancer among indigenous populations despite research on oral health disparities in this group. INCLUSION CRITERIA: Inclusion criteria involve studies on the burden of oral cancer and pre-cancerous lesions in indigenous groups, considering rates, ratios (prevalence or mortality), or survival proportions. Databases will be searched from inception to the present, with no limitations on study design, language, age, gender, or geography. We will exclude studies that only identify, diagnose, or screen oral cancer and pre-cancerous lesions without mentioning prevalence and incidence. METHODS: This review will follow to the JBI methodology for systematic reviews of prevalence and incidence. Databases to be searched will include MEDLINE (Ovid), Embase (Ovid), CINAHL (EBSCOhost), Cochrane Central Register of Controlled Trials, Scopus, and Dentistry and Oral Sciences Source (EBSCOhost). ProQuest Dissertations and Theses, OAIster, International Association for Dental Research conference abstracts, Google Scholar, government reports, and cancer registry reports will be screened for unpublished studies. Two reviewers will independently screen articles, and data will be extracted using a customized form. Narrative data synthesis will be conducted, and where appropriate, meta-analysis using JBI SUMARI. Methodological quality will be assessed using JBI's critical appraisal tool for prevalence studies. REVIEW REGISTRATION NUMBER: PROSPERO CRD42023402858.

Enablers and Barriers to the Scaling Up of Pneumococcal Conjugate Vaccine in India During the COVID-19 Pandemic: A Qualitative Study.

Background: Pneumonia is one of the leading causes of death in under-5 children in India. This led the Ministry of Health & Family Welfare (MoHFW) in India to decide for the nationwide roll-out of the Pneumococcal Conjugate Vaccine (PCV). However, the introduction of PCV became more complex in the face of unprecedented challenges set forth by the COVID-19 pandemic. The study aims to assess enablers and barriers to the introduction of PCV in India during the pandemic. Methodology: Qualitative research approach involving key-informant interviews from John Snow India (JSI), the lead technical agency that supported MoHFW in the PCV expansion was employed to delineate the enablers and barriers. Principle of saturation was employed to derive the sample size. Thematic analysis using inductive approach was based on the modified World Health Organization (WHO) framework for new vaccine introduction impact on the Immunization and Health Systems, using NVIVO 12 qualitative data analysis software. Results: A total of 11 key informants (4 national-level program managers and 7 state technical officers) were telephonically interviewed. The study found social acceptance, lower cost of the vaccine, and intensive communication activities as potential enablers. Other enablers for PCV introduction included a robust vaccine supply-chain system, ample cold-chain space availability, and strong political commitment, despite the ongoing second wave. Further, the identified barriers included poor physical access, insufficient social mobilization, and limited advocacy along with a stretched workforce. Conclusion: The study delineated several enablers and barriers to introducing PCV in the country during the pandemic. The existing barriers in the PCV roll-out prompted the need to address these gaps, making key program-based recommendations to improve future new vaccine introductions during the pandemic.

Critical factors in the successful expansion of Pneumococcal Conjugate Vaccine in India during the COVID-19 pandemic.

India had decided to roll out PCV in India in 2015, but successful implementation of any new vaccine introduction mandates an enormous effort. PCV was scaled up during the COVID-19 pandemic, which posed new, unprecedented challenges in the vaccine rollout. However, India successfully expanded PCV in the country in record time across all states and Union Territories. During the pandemic, supply-side restrictions, delayed vaccine shipments, staff shortages, and restrictions in conducting training negatively affected the roll-out of PCV across the country. However, despite the ongoing pandemic, India successfully rolled out PCV across the country in 7 months. In this review, the authors have conducted a narrative review to delineate the crucial factors that helped in the successful expansion of PCV.